123 related articles for article (PubMed ID: 38636395)
21. STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.
Huang DY; Chao Y; Tai MH; Yu YH; Lin WW
J Biomed Sci; 2012 Mar; 19(1):35. PubMed ID: 22462553
[TBL] [Abstract][Full Text] [Related]
22. Citrus-derived DHCP inhibits mitochondrial complex II to enhance TRAIL sensitivity via ROS-induced DR5 upregulation.
Chen L; Hao M; Yan J; Sun L; Tai G; Cheng H; Zhou Y
J Biol Chem; 2021; 296():100515. PubMed ID: 33676890
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation.
Hörnich BF; Großkopf AK; Schlagowski S; Tenbusch M; Kleine-Weber H; Neipel F; Stahl-Hennig C; Hahn AS
J Virol; 2021 Apr; 95(9):. PubMed ID: 33608407
[TBL] [Abstract][Full Text] [Related]
24. High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer.
De Miguel D; Gallego-Lleyda A; Ayuso JM; Pejenaute-Ochoa D; Jarauta V; Marzo I; Fernández LJ; Ochoa I; Conde B; Anel A; Martinez-Lostao L
Cancer Lett; 2016 Dec; 383(2):250-260. PubMed ID: 27725224
[TBL] [Abstract][Full Text] [Related]
25. Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts.
Psahoulia FH; Drosopoulos KG; Doubravska L; Andera L; Pintzas A
Mol Cancer Ther; 2007 Sep; 6(9):2591-9. PubMed ID: 17876056
[TBL] [Abstract][Full Text] [Related]
26. Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways.
Tam A; Kulkarni J; An K; Li L; Dorscheid DR; Singhera GK; Bernatchez P; Reid G; Chan K; Witzigmann D; Cullis PR; Sin DD; Lim CJ
Eur J Pharm Sci; 2022 Sep; 176():106234. PubMed ID: 35688311
[TBL] [Abstract][Full Text] [Related]
27. BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-κB.
Du J; Wang Y; Chen D; Ji G; Ma Q; Liao S; Zheng Y; Zhang J; Hou Y
Cancer Lett; 2016 Dec; 383(2):145-153. PubMed ID: 27721019
[TBL] [Abstract][Full Text] [Related]
28. PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation.
Tanaka H; Hoshikawa Y; Oh-hara T; Koike S; Naito M; Noda T; Arai H; Tsuruo T; Fujita N
Mol Cancer Res; 2009 Apr; 7(4):557-69. PubMed ID: 19372584
[TBL] [Abstract][Full Text] [Related]
29. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
[TBL] [Abstract][Full Text] [Related]
30. Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry.
Haga S; Yamamoto N; Nakai-Murakami C; Osawa Y; Tokunaga K; Sata T; Yamamoto N; Sasazuki T; Ishizaka Y
Proc Natl Acad Sci U S A; 2008 Jun; 105(22):7809-14. PubMed ID: 18490652
[TBL] [Abstract][Full Text] [Related]
31. Variations in Cell Surface ACE2 Levels Alter Direct Binding of SARS-CoV-2 Spike Protein and Viral Infectivity: Implications for Measuring Spike Protein Interactions with Animal ACE2 Orthologs.
Kazemi S; López-Muñoz AD; Hollý J; Jin L; Yewdell JW; Dolan BP
J Virol; 2022 Sep; 96(17):e0025622. PubMed ID: 36000847
[TBL] [Abstract][Full Text] [Related]
32. Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA).
Álvarez-Benedicto E; Farbiak L; Márquez Ramírez M; Wang X; Johnson LT; Mian O; Guerrero ED; Siegwart DJ
Biomater Sci; 2022 Jan; 10(2):549-559. PubMed ID: 34904974
[TBL] [Abstract][Full Text] [Related]
33. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
[TBL] [Abstract][Full Text] [Related]
34. Novel Ionizable Lipid Nanoparticles for SARS-CoV-2 Omicron mRNA Delivery.
Long J; Yu C; Zhang H; Cao Y; Sang Y; Lu H; Zhang Z; Wang X; Wang H; Song G; Yang J; Wang S
Adv Healthc Mater; 2023 May; 12(13):e2202590. PubMed ID: 36716702
[TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 deregulates the vascular and immune functions of brain pericytes via Spike protein.
Khaddaj-Mallat R; Aldib N; Bernard M; Paquette AS; Ferreira A; Lecordier S; Saghatelyan A; Flamand L; ElAli A
Neurobiol Dis; 2021 Dec; 161():105561. PubMed ID: 34780863
[TBL] [Abstract][Full Text] [Related]
36. An engineered nano-liposome-human ACE2 decoy neutralizes SARS-CoV-2 Spike protein-induced inflammation in both murine and human macrophages.
Satta S; Meng Z; Hernandez R; Cavallero S; Zhou T; Hsiai TK; Zhou C
Theranostics; 2022; 12(6):2639-2657. PubMed ID: 35401811
[No Abstract] [Full Text] [Related]
37. Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides.
Llewellyn GN; Chen HY; Rogers GL; Huang X; Sell PJ; Henley JE; Cannon PM
J Virol; 2023 Aug; 97(8):e0068423. PubMed ID: 37555663
[TBL] [Abstract][Full Text] [Related]
38. Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice.
Huang K; Zhang Y; Hui X; Zhao Y; Gong W; Wang T; Zhang S; Yang Y; Deng F; Zhang Q; Chen X; Yang Y; Sun X; Chen H; Tao YJ; Zou Z; Jin M
EBioMedicine; 2021 May; 67():103381. PubMed ID: 33993052
[TBL] [Abstract][Full Text] [Related]
39. Specific delivering of RNAi using Spike's aptamer-functionalized lipid nanoparticles for targeting SARS-CoV-2: A strong anti-Covid drug in a clinical case study.
Saify Nabiabad H; Amini M; Demirdas S
Chem Biol Drug Des; 2022 Feb; 99(2):233-246. PubMed ID: 34714580
[TBL] [Abstract][Full Text] [Related]
40. Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer.
Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi YW; Choi HG; Park ES; Lee KC; Youn YS
Pharm Res; 2016 Mar; 33(3):615-26. PubMed ID: 26526555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
